West Pharmaceutical Services/$WST

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About West Pharmaceutical Services

West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

Ticker

$WST

Primary listing

NYSE

Industry

Life Sciences Tools & Services

Employees

10,600

ISIN

US9553061055

WST Metrics

BasicAdvanced
$16B
34.19
$6.37
1.22
$0.83
0.39%

What the Analysts think about WST

Analyst ratings (Buy, Hold, Sell) for West Pharmaceutical Services stock.

Bulls say / Bears say

West Pharmaceutical Services raised its annual profit and sales forecasts for 2025, citing benefits from a weaker U.S. dollar and anticipated strong demand for medical devices. (reuters.com)
The company reported Q1 2025 adjusted earnings per share of $1.45, surpassing analyst expectations of $1.23, indicating strong financial performance. (benzinga.com)
Analysts at Evercore ISI Group initiated coverage on West Pharmaceutical Services with an 'Outperform' rating and a price target of $275, reflecting confidence in the company's growth prospects. (benzinga.com)
West Pharmaceutical Services projected adjusted EPS of $6.00-$6.20 for full-year 2025, significantly below the consensus estimate of $7.44, leading to a stock price decline of over 38% following the earnings release. (monexa.ai)
The company anticipates a $20 to $25 million impact from recently implemented tariffs for the remainder of 2025, which could affect profitability. (benzinga.com)
West Pharmaceutical Services' operating margin declined to 15.3% in Q1 2025 from 17.7% in the same quarter last year, indicating potential challenges in maintaining profitability. (finviz.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jun 2025.

WST Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

WST Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $WST

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

Jul30
West Pharmaceutical Services
Dividend·Ex-dividend
Aug6
West Pharmaceutical Services
Dividend·Payment
$0.21Per share
FAQs